(ImmunoTherapies Activated with NAP for efficient Killing) to be used in the fight against cancer.
See Elicera Therapeutics’ presentation below.
Gothenburg-based Elicera Therapeutics, headed by CEO Jamal El-Mosleh, travelled to Stockholm to present the company at the BioStock Investor Meeting. The cell and gene therapy company has developed a universal CAR T-cell-enhancement technology platform called iTANK
(ImmunoTherapies Activated with NAP for efficient Killing) to be used in the fight against cancer.
See Elicera Therapeutics’ presentation below.
Expand your understanding of new markets, striking global partnerships and attracting international capital. Find new opportunities and learn how to...
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa kontoHar du synpunkter eller nyhetstips?
Mejla till [email protected]